published meta-analysis   sensitivity analysis   studies

lopinavir/ritonavir in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsCao, 2020 0.71 [0.36; 1.40] REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06] 0.81[0.65; 1.03]Cao, 2020, REMAP-CAP (lopinavir/ritonavir only), 202020%844moderatenot evaluable deaths (time to event analysis only)detailed resultsREMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06] 0.83[0.65; 1.06]REMAP-CAP (lopinavir/ritonavir only), 202010%645NAnot evaluable clinical improvementdetailed resultsCao, 2020 1.31 [0.94; 1.83] 1.31[0.94; 1.83]Cao, 202010%NAnot evaluable clinical improvement (14-day)detailed resultsCao, 2020 1.94 [1.09; 3.48] REMAP-CAP (lopinavir/ritonavir only), 2020 0.85 [0.64; 1.12] 1.23[0.55; 2.76]Cao, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020284%844moderatenot evaluable clinical improvement (28-day)detailed resultsCao, 2020 1.59 [0.84; 3.03] 1.59[0.84; 3.03]Cao, 202010%199NAnot evaluable clinical improvement (7-day)detailed resultsCao, 2020 3.16 [0.62; 16.06] 3.16[0.62; 16.06]Cao, 202010%199NAnot evaluable clinical improvement (time to event analysis only)detailed resultsCao, 2020 1.31 [0.94; 1.83] 1.31[0.94; 1.83]Cao, 202010%NAnot evaluable hospital dischargedetailed resultsREMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.69; 1.00] 0.83[0.69; 1.00]REMAP-CAP (lopinavir/ritonavir only), 202010%645NAnot evaluable serious adverse eventsdetailed resultsCao, 2020 0.52 [0.27; 1.01] REMAP-CAP (lopinavir/ritonavir only), 2020 1.57 [0.70; 3.49] 0.88[0.30; 2.58]Cao, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020277%811moderatenot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-03-28 21:24 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 509 - roots T: 290